A 58-year-old woman with a 9-year history of seropositive rheumatoid arthritis on weekly methotrexate 15 mg presents with 6 weeks of progressive dry cough and dyspnea on exertion. HRCT shows bilateral ground-glass opacities with basal predominance and centrilobular nodules. Bronchoalveolar lavage demonstrates lymphocytic alveolitis with markedly reduced CD4/CD8 ratio. Pulmonary function testing is performed. The parameter marked **C** in the diagram (DLCO 48% predicted) is markedly reduced, while FEV1/FVC ratio remains preserved at 0.82. Which of the following best explains the clinical significance of the disproportionately reduced DLCO in this patient?
A. It is the most sensitive functional marker of early methotrexate-induced hypersensitivity pneumonitis and the best predictor of progression if the offending agent is not withdrawn
B. It suggests concurrent pulmonary hypertension and necessitates immediate echocardiography before any further investigation
C. It indicates the presence of significant airflow obstruction that requires bronchodilator therapy
D. It reflects the restrictive pattern due to reduced lung volumes and is proportional to the degree of pulmonary fibrosis
Explanation
Why option 1 is correct
The markedly reduced DLCO (48% predicted) with DLCO/VA also reduced at 60% predicted indicates impaired gas transfer across the alveolar-capillary membrane out of proportion to the volume loss. According to Conway R, Carey JJ (2023) and ATS/ERS Hypersensitivity Pneumonitis Guidelines 2020, this disproportionately reduced DLCO is the most sensitive functional marker of early methotrexate-induced pneumonitis and the best predictor of subsequent progression if the offending agent is not withdrawn. Serial DLCO is the recommended monitoring parameter, as it falls before symptomatic deterioration. In this patient, the preserved FEV1/FVC ratio (0.82) and absence of airflow obstruction rule out obstructive disease, making the DLCO the critical discriminator of interstitial lung disease severity and prognosis.
Why each distractor is wrong
Option 2: The FEV1/FVC ratio is preserved at 0.82 (normal >0.70), explicitly ruling out airflow obstruction. A reduced DLCO with preserved spirometry is characteristic of interstitial/alveolar disease, not obstructive airway disease. Bronchodilators are not indicated.
Option 3: While the TLC is reduced (70% predicted), the DLCO reduction (48% predicted) is disproportionately severe relative to the volume loss. A DLCO/VA of 60% predicted indicates the defect is not simply proportional to volume restriction but reflects true alveolar-capillary membrane dysfunction—the hallmark of hypersensitivity pneumonitis, not pure pulmonary fibrosis at this stage.
Option 4: Although methotrexate-induced pneumonitis can progress to pulmonary hypertension, the clinical presentation and PFT pattern here are diagnostic of hypersensitivity pneumonitis itself. The reduced DLCO is a marker of alveolar inflammation and gas-exchange impairment, not a direct indicator of pulmonary hypertension. Echocardiography is not the next step; discontinuation of methotrexate and serial DLCO monitoring are.
High-YieldNEET PG
In drug-induced interstitial lung disease, a markedly reduced DLCO out of proportion to spirometric restriction is the earliest and most sensitive marker of alveolar-capillary injury; serial DLCO monitoring predicts progression better than imaging or symptoms alone.
